Active
Besloten Vennootschap · Tongeren-Borgloon · since 2022
Impact Omics
Impact Omics (besloten vennootschap) is an active company registered in 3840 Tongeren-Borgloon, enterprise number 0779.683.030. Main activity: Activiteiten van medische beeldvorming en medische laboratoria.
- Peppol
- Enterprise number
- 0779.683.030
- VAT number
- BE0779683030
- Start date
- 4 January 20224 years
- Legal form
- Besloten Vennootschap
- Location
- Tongersesteenweg 153840 Tongeren-Borgloon
Source: KBO/BCE open data, FPS Economy · data as of 7 November 2026
Details
- Legal situation
- Normale toestand
- EUID
- BEKBOBCE.0779.683.030
Management
Directors, capital, fiscal year and qualifications are not in the open data. We fetch them from the FPS Economy's KBO Public Search.
Publications of Impact Omics
This company's deeds and changes, such as its articles of association, appointments and moves of its registered office, are published in the annexes to the Belgian Official Gazette (Belgisch Staatsblad / Moniteur belge).
View publications on eJustice (in Dutch) (opens in a new tab)Source: Belgian Official Gazette, FPS Justice
E-invoicing
Checked on 6 November 2026
Reachable on Peppol
- Receives invoices
- Yes
- Receives credit notes
- Yes
- Peppol ID
- 0208:0779683030
- 9925:BE0779683030
Activities
- Activiteiten van medische beeldvorming en medische laboratoriaNACE-BEL 86910Main activity
- Speur- en ontwikkelingswerk op biotechnologisch gebiedNACE-BEL 72101
- Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebiedNACE-BEL 72109
Establishments
1 establishment
- Ambachtenlaan 13001 Leuven2110001 Onderzoek en op punt stellen van de productie van actief geneeskrachtige substanties, bestemd voor de vervaardiging van geneesmiddelenSince 4 January 20222.327.225.285View on map
History
4 January 2022
Establishment opened
Establishment 2.327.225.285- Based on the KBO start date
4 January 2022
Registered with the KBO
- Based on the KBO start date
Similar companies
Active companies with the same activity in 3840 Tongeren-Borgloon.